Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results